Post-IPO, Cardlytics CEO Scott Grimes Looks Towards International Expansion, Potential M&A
This past February, Martech company Cardlytics (CDLX) rang the NASDAQ bell to announce the pricing of its public common stock offering, closing the day slightly above their initial price of $13 (at $13.37 per share).
But that morning, as they headed over to Wall Street, the DOW was down